Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2025-3968

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial

Attaya Suvannasankha, Jonathan Kaufman, Ashraf Badros, Michel Pavic, Hock Choong Lai, Muhammad S. Raza, Parth S. Shah, Patrick Mueller, Jorge Acosta, Margaret Hoyle, Erik Vandendries, Jay Cheng, Alexander Lesokhin

Blood (2025) 146 (Supplement 1): 100.

https://doi.org/10.1182/blood-2025-100

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach, Shannon Miller, Pedro Vianna, Emily Simpson, Madison Chuma, Brendan Fink, Samantha Geberth, Emily Magnavita, Jack Khouri, James Hoffman, Jonathan Kaufman, Vaishali Sanchorawala, Raymond Comenzo, Giada Bianchi

Blood (2025) 146 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2025-5808

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada, Vikas Gupta, Craig Hofmeister, Nishi Shah, Jonathan Kaufman, Sagar Lonial, Ajay Nooka

Blood (2025) 146 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2025-2301

Published: 2025

Journal Articles

How I treat high-risk myeloma

Sagar Lonial, Lawrence H. Boise, Jonathan Kaufman

Blood (2015) 126 (13): 1536–1543.

https://doi.org/10.1182/blood-2015-06-653261

Published: 2015

Journal Articles

Platelet and Fibrin Alterations on Thromboelastography in Children Undergoing Congenital Cardiac Surgery with Cardiopulmonary Bypass

Kim S. John, MD, Elizabeth Villalobos-Menuey, MS, Matthew Hathaway, Abimbola Onasoga, PhD, Jonathan Kaufman, MD, Eduardo DaCruz, MD, Jorge DiPaola, MD, Marilyn J. Manco-Johnson, MD

Blood (2014) 124 (21): 4194.

https://doi.org/10.1182/blood.V124.21.4194.4194

Published: 2014

Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath

Blood (2009) 114 (22): 432.

https://doi.org/10.1182/blood.V114.22.432.432

Published: 2009

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Claire Torre, Amelia Langston, Mary J. Lechowicz, Christopher Flowers, Stephanie McMillan, Heather Renfroe, Leonard T Heffner, Edmund K Waller

Blood (2008) 112 (11): 3332.

https://doi.org/10.1182/blood.V112.11.3332.3332

Published: 2008

Journal Articles

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Jonathan Kaufman, MD, Ruben Niesvizky, MD, Edward A. Stadtmauer, MD, Asher Chanan-Khan, MD, David Siegel, MD, PhD, Heather Horne, Nick Teoh, PhD, Matthew J. Leoni, MD, William A Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 3697.

https://doi.org/10.1182/blood.V112.11.3697.3697

Published: 2008

Journal Articles

A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Dixil Francis, Chatchada Karanes, Suzanne Trudel, Donna E. Reece, MD, Amrita Krishnan, Marc Buacharern, Renee Smith, Faraz Zaman, Engin Gul, Akari M. Dollard, Donald Harvey, Jonathan Kaufman

Blood (2008) 112 (11): 3706.

https://doi.org/10.1182/blood.V112.11.3706.3706

Published: 2008

Journal Articles

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD, Stephanie McMillan, RN, Leonard T. Heffner, MD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD, Morgan L. McLemore, MD, Rajni Sinha, MD, Mary J Lechowicz, MD, H. Jean Khoury, MD, Elliott F. Winton, MD

Blood (2008) 112 (11): 3644.

https://doi.org/10.1182/blood.V112.11.3644.3644

Published: 2008

Journal Articles

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

Andrzej Jakubowiak, Todd Zimmerman, Melissa Alsina, Paul Richardson, Jonathan Kaufman, T. Kendall, C. Brozo, A. McAllister, C. Leister, T. Hideshima, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Giusti, Kenneth Anderson

Blood (2007) 110 (11): 1169.

https://doi.org/10.1182/blood.V110.11.1169.1169

Published: 2007

Journal Articles

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

Amitabha Mazumder, MD, Jonathan Kaufman, MD, Sagar Lonial, MD, Sundar Jagannath, MD, David Vesole, MD, PhD

Blood (2007) 110 (11): 3612.

https://doi.org/10.1182/blood.V110.11.3612.3612

Published: 2007

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Amelia A. Langston, MD, Leonard T. Heffner, MD, Claire Torre, Mary J. Lechowicz, MD, Christopher Flowers, MD, Stephanie McMillan, RN, Michael Arnold, Ned K. Waller, MD, PhD

Blood (2007) 110 (11): 949.

https://doi.org/10.1182/blood.V110.11.949.949

Published: 2007

Journal Articles

T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT).

Laura Vann, Milcah Larks, MD, Christopher Flowers, MD, Sagar Lonial, MD, Jonathan Kaufman, MD, Mary Jo Lechowicz, MD, Amelia A. Langston, MD, Jean Khoury, MD, Ned Waller, MD,PhD

Blood (2006) 108 (11): 3224.

https://doi.org/10.1182/blood.V108.11.3224.3224

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

How I treat high-risk myeloma

Platelet and Fibrin Alterations on Thromboelastography in Children Undergoing Congenital Cardiac Surgery with Cardiopulmonary Bypass

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only